Zacks Research Forecasts Haemonetics’ Q3 Earnings (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Analysts at Zacks Research upped their Q3 2026 EPS estimates for shares of Haemonetics in a research note issued to investors on Monday, February 17th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $1.33 for the quarter, up from their prior forecast of $1.31. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2027 earnings at $1.48 EPS.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%.

HAE has been the subject of a number of other reports. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and reduced their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. JMP Securities reduced their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC reduced their price target on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Finally, Barrington Research cut their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Stock Down 0.5 %

Shares of Haemonetics stock opened at $63.36 on Thursday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The stock has a market capitalization of $3.18 billion, a PE ratio of 24.95, a price-to-earnings-growth ratio of 1.12 and a beta of 0.39. Haemonetics has a 52-week low of $58.80 and a 52-week high of $97.97. The company has a 50-day simple moving average of $72.98 and a two-hundred day simple moving average of $76.76.

Hedge Funds Weigh In On Haemonetics

Several large investors have recently added to or reduced their stakes in HAE. Vontobel Holding Ltd. lifted its holdings in Haemonetics by 3.8% during the third quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock valued at $392,000 after purchasing an additional 180 shares in the last quarter. Riverwater Partners LLC lifted its holdings in Haemonetics by 185.0% during the third quarter. Riverwater Partners LLC now owns 44,841 shares of the medical instruments supplier’s stock valued at $3,556,000 after purchasing an additional 29,109 shares in the last quarter. Keene & Associates Inc. lifted its holdings in shares of Haemonetics by 3.0% in the third quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock worth $818,000 after buying an additional 298 shares in the last quarter. CWC Advisors LLC. purchased a new position in shares of Haemonetics in the third quarter worth $231,000. Finally, Boston Trust Walden Corp lifted its holdings in shares of Haemonetics by 13.8% in the third quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier’s stock worth $65,076,000 after buying an additional 98,019 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.